Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.35 |
| ▸ | PNP | P00491 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661419 | 1.00 | HSP90AA1 (0.35) | HSP90AA1TRAP1PNPMAPTHSP90B1 | |
| SCHEMBL25875898 | 0.89 | MAPT (0.33) | PNPMAPTPDE2ADGAT1 | |
| SCHEMBL26720567 | 0.89 | HSP90AA1 (0.36) | HSP90AA1TRAP1PNPMAPTHSP90B1 | |
| SCHEMBL21481639 | 0.88 | NT5E (0.38) | HSP90AA1TRAP1PNPMAPTPDE2A | |
| SCHEMBL21303003 | 0.87 | MAPT (0.32) | HSP90AA1TRAP1PNPMAPTPDE2A | |
| SCHEMBL4015126 | 0.86 | ABL1 (0.38) | ADORA1 | |
| SCHEMBL1441946 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL20262422 | 0.81 | DGAT1 (0.33) | MAPTDGAT1 | |
| SCHEMBL26102605 | 0.79 | BCDIN3D (0.42) | MAPTPDE2A | |
| SCHEMBL31138676 | 0.78 | TUBB4A (0.32) | MAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | HSP90AA1 2431/4885TRAP1 1898/4885PNP 2974/4885 |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | HSP90AA1 4378/4885TRAP1 4597/4885PNP 3423/4885 |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | ERBB2, EGFR, ERBB3 | HSP90AA1 1543/4885TRAP1 2528/4885PNP 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.